Shaping the Future of Immuno-Oncology: Current Challenges and Breakthroughs in Biotech

​Interested in the latest developments in the immuno-oncology field? Curious about the challenges researchers face in bringing new immunotherapies to patients? Join us for an exciting panel discussion of experts, discussing the current R&D landscape, explore key breakthroughs, and address the pressing challenges in the biotech space. This event will offer insights into the future of cancer immunotherapy and its growing impact in biotech.

Our Panelists:

• ​Maria Sjöstrand, phD: Dr. Sjostrand is currently an Associate Director at Sanavia Oncology. She holds a PhD from the Karolinska Institute, Sweden, where she studied molecular mechanisms behind autoimmune disease. After completing her studies, Dr. Sjostrand performed a postdoc at Memorial Sloan Kettering Cancer Center in New York with Dr. Michel Sadelain, where she focused on developing chimeric antigen receptor (CAR) T cell therapies to treat cancer. At Sanavia Oncology, Dr. Sjostrand is designing novel strategies to treat cancers.

• ​Chad May, phD: Dr. May is a Biotech executive that has led preclinical research and development teams across a variety of biotherapeutic programs and platforms. He is currently the
  Head of Serotiny, Therapeutics Design & Development at Johnson & Johnson Innovative Medicine.

• ​Theodoros Giavridis, phD: Theodore Giavridis is currently Head of Preclinical R&D at OverT Bio Inc., a γδ T cell therapy company committed to delivering next generation allogeneic cell therapies for patients with solid tumors. Theodore completed his undergraduate studies in the University of Patras Greece and he pursued his graduate education at Columbia University and Weill Cornell, where he studied cell therapy under the supervision of Dr. Michel Sadelain. Prior to his current position, Theodore was also part of Arsenal Biosciences Inc., and Mnemo Therapeutics Inc., both cell therapy companies.